{
    "root": "d3acb3e2-b097-4d9e-87ff-3e6a83c20734",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "ADDYI",
    "value": "20250318",
    "ingredients": [
        {
            "name": "Flibanserin",
            "code": "37JK4STR6Z"
        },
        {
            "name": "Lactose Monohydrate",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "Microcrystalline Cellulose",
            "code": "OP1R32D61U"
        },
        {
            "name": "Hypromellose, Unspecified",
            "code": "3NXW29V3WO"
        },
        {
            "name": "Croscarmellose Sodium",
            "code": "M28OL1HH48"
        },
        {
            "name": "Magnesium Stearate",
            "code": "70097M6I30"
        },
        {
            "name": "Talc",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "Polyethylene Glycol, Unspecified",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "Titanium Dioxide",
            "code": "15FIX9V2JP"
        },
        {
            "name": "Ferric Oxide Red",
            "code": "1K09F3G675"
        }
    ],
    "indications": "addyi indicated treatment premenopausal women acquired , generalized hypoactive sexual desire disorder ( hsdd ) , characterized low sexual desire causes marked distress interpersonal difficulty due : •a co-existing medical psychiatric condition , •problems within relationship , •the effects medication substance . acquired hsdd refers hsdd develops patient previously problems sexual desire . generalized hsdd refers hsdd occurs regardless type stimulation , situation partner . limitations •addyi indicated treatment hsdd postmenopausal women men . •addyi indicated enhance sexual performance .",
    "contraindications": "• recommended 100 mg taken daily bedtime ( 2.1 ) • addyi dosed bedtime waking hours increases risks hypotension , syncope , accidental injury , central nervous system ( cns ) depression ( 2.1 ) • discontinue treatment 8 weeks improvement ( 2.3 )",
    "warningsAndPrecautions": "addyi available 100 mg oval , pink , film-coated tablet debossed one side “ f100 ” blank side . available bottles 30 tablets . ( ndc 58604-214-30 ) storage store 25°c ( 77°f ) ; excursions permitted 15°-30°c ( 59°-86°f ) [ usp controlled room temperature ] .",
    "adverseReactions": "addyi contraindicated patients : •using concomitant moderate strong cyp3a4 inhibitors [ boxed warning ( 5.2 ) ] . •with hepatic impairment [ boxed warning ( 5.5 ) ] . • known hypersensitivity addyi components . , including anaphylaxis , consistent angioedema ( e.g . , swelling face , lips , mouth ) , pruritus , urticaria reported [ ( 6.2 ) ] .",
    "indications_original": "ADDYI is indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is NOT due to: \n                  \n                     \n                        •A co-existing medical or psychiatric condition,\n                     \n                        •Problems within the relationship, or\n                     \n                        •The effects of a medication or other drug substance.\n                  \n                  Acquired HSDD refers to HSDD that develops in a patient who previously had no problems with sexual desire. Generalized HSDD refers to HSDD that occurs regardless of the type of stimulation, situation or partner. \n                  \n                     Limitations of Use\n                  \n                  \n                     \n                        •ADDYI is not indicated for the treatment of HSDD in postmenopausal women or in men.\n                     \n                        •ADDYI is not indicated to enhance sexual performance.",
    "contraindications_original": "• Recommended dosage is 100 mg taken once daily at bedtime (2.1) • ADDYI is dosed at bedtime because administration during waking hours increases risks of hypotension, syncope, accidental injury, and central nervous system (CNS) depression (2.1) • Discontinue treatment after 8 weeks if no improvement (2.3)",
    "warningsAndPrecautions_original": "ADDYI is available as a 100 mg oval, pink, film-coated tablet debossed on one side with “f100” and blank on the other side.  Available in bottles of 30 tablets.  (NDC 58604-214-30)\n                  \n                     Storage\n                     Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F) [see USP controlled room temperature].",
    "adverseReactions_original": "ADDYI is contraindicated in patients:\n                  \n                     \n                        •Using concomitant moderate or strong CYP3A4 inhibitors [see \n                              Boxed Warning\n                            and \n                              Warnings and Precautions (5.2)\n                           ].\n                     \n                        •With hepatic impairment [see \n                              Boxed Warning\n                            and \n                              Warnings and Precautions (5.5)\n                           ].\n                     \n                        •\n                        With known hypersensitivity to ADDYI or any of its components. Reactions, including anaphylaxis, reactions consistent with angioedema (e.g., swelling of the face, lips, and mouth), pruritus, and urticaria have been reported [see \n                                 Adverse Reactions (6.2)\n                              ]."
}